axitinib

Overview

Axitinib is a selective inhibitor of vascular endothelial growth factor receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4), approved for second-line treatment of renal cell carcinoma. It is used in combination with immune checkpoint inhibitors (e.g., avelumab+axitinib in the JAVELIN Renal 101 trial) for first-line ccRCC.

Evidence in the corpus

  • Patients classified as ICI/ICI-combo-preferred by the HiTME model had significantly longer PFS with avelumab+axitinib vs. sunitinib (JAVELIN Renal 101, p = 0.000007) PMID:22138691.
  • The TKI response model (which includes axitinib-based regimens) achieved ROC-AUC = 0.74 on validation (n = 822), outperforming single-biomarker signatures PMID:22138691.
  • JAVELIN Renal 101 (avelumab+axitinib) was one of the clinical trial datasets used to train and validate the ccRCC IO/TKI response decision-tree model PMID:22138691.
  • Cited as a VEGFR2-targeting TKI among anti-angiogenic agents under investigation in R/M NPC PMID:24952746

Resistance mechanisms

Cancer types (linked)

  • clear cell renal cell carcinoma (CCRCC)

Sources

This page was processed by entity-page-writer on 2026-05-06. - PMID:24952746

This page was processed by wiki-cli on 2026-05-11.